Results 121 to 130 of about 1,008,050 (263)

A perioperative medicine platform trial (PROMPT) evaluating interventions to reduce the risk of infection and other major complications after surgery: rationale and design. [PDF]

BJA Open
Myles PS, Peel TN, Webb S, Wallace SK, Brown WA, Corcoran T, Bucknall T, Coulson T, Frei D, Mitchell B, Ayton D, Higgins AM, Forbes A, Spencer R, Ryan EG.   +14 more
europepmc   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch, Markus Matilainen, Giulia N. Baldrighi, Marjo Nylund, Maija Saraste, Laura Airas   +5 more
wiley   +1 more source

Unravelling HCV diversity and resistance in Viet Nam: a cross-sectional analysis. [PDF]

Lancet Reg Health West Pac
Le Ngoc C, Chai H, Airey G, Das T, Jennings D, Xu F, Flower B, Marjaneh MM, McCabe L, Le Manh H, Nguyen Van Vinh C, Trong TD, Ngoc TP, Thi Thu HV, Thwaites GE, van Doorn HR, Day J, Kestelyn E, Le Van T, Rahman M, Pett S, Barnes E, Walker AS, Cooke GS, Ansari MA.   +24 more
europepmc   +1 more source

Committee on Regional Sections

Journal of AOAC INTERNATIONAL, 1989
openaire   +1 more source

Natural Frequencies of Levodopa‐Induced Dyskinesia in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Abnormal involuntary movements, known as dyskinesias, are common complications of levodopa treatment in patients with Parkinson's disease and can significantly impair quality of life. The underlying pathophysiology remains unclear, and current therapeutic options are limited.
Ioannis U. Isaias, Federica Avantaggiato, Gianni Pezzoli, Andrea Canessa   +3 more
wiley   +1 more source

Global trends, projections, and inequalities in neonatal sudden infant death syndrome mortality attributable to risk factors from 1990 to 2021. [PDF]

Transl Pediatr
Jia T, Wang Y, Zhang S, Zhao G, Wang W, Yang G.   +5 more
europepmc   +1 more source

Temporal Interference Stimulation of Centromedian‐Parafascicular Complex in Disorders of Consciousness: A Pilot Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Treatment of disorders of consciousness (DoC) remains a major clinical challenge, and noninvasive, targeted modulation of deep brain structures has emerged as a promising therapeutic strategy. We aimed to evaluate the feasibility/safety and preliminary effects of thalamic temporal interference stimulation (TIS) targeting centromedian‐
Gengyao Hu, Changgeng Song, Dianwei Wu, Xiaoqian Niu, Jianmin Hao, Lijuan Liu, Xiaogang Kang, Wen Jiang   +7 more
wiley   +1 more source

Validation of a Cellular Imaging‐Based Method as a Potential Biomarker for SPG4 Hereditary Spastic Paraplegia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Hereditary Spastic Paraplegia (HSP) comprises a group of rare genetic diseases characterized by length‐dependent axonal degeneration of the corticospinal tracts and dorsal columns, whose main clinical feature is spastic gait. Pathogenic variants in the SPG4 gene cause Spastic Paraplegia Type 4 (SPG4‐HSP), the most common form of HSP.
Gaia Fattorini, Valerio Licursi, Gianmarco Dalla Zanna, Flavio Dal Canto, Melissa Barghigiani, Nunzio Setola, Salvatore Rossi, Antonio Funcis, Filippo M. Santorelli, Gabriella Silvestri, Carlo Casali, Francesca Sardina, Cinzia Rinaldo   +12 more
wiley   +1 more source

Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey. [PDF]

BMC Prim Care
Sundell I, Wettermark B, Sundström A, Martinell M, Ericsson B, Lindahl U, Rubaiy HN, Ekbäck MP.   +7 more
europepmc   +1 more source

Vascular Disease, Non‐Steroidal Anti‐Inflammatory Drugs and Risk of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives A history of vascular disease has been shown to be associated with an increased risk of Parkinson's disease, but this may be due to reverse causation. In addition, non‐steroidal anti‐inflammatory drugs are thought to reduce Parkinson's disease risk, but evidence is inconsistent and confounding by prior vascular disease is possible ...
Clare Wotton, Carol Hermon, Sarah Floud, Gillian Reeves, Isobel Barnes   +4 more
wiley   +1 more source